Jazz Pharmaceuticals PLC

Healthcare · Biotechnology

236.30$ +0.6% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Income Statement

Jazz Pharmaceuticals PLC (JAZZ) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 1,208 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement JAZZ
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	374	397	376	394	412	436	445	500	469	476	508	534	538	582	535	562	601	666	608	752	838	897	814	933	941	972	893	957	972	1,012	902	1,024	1,055	1,088	898	1,046	1,126	1,198	1,069	1,208	4,601
Cost of Revenue	24	34	25	29	31	25	34	35	27	26	34	28	31	35	29	28	42	50	40	119	145	136	115	124	134	167	129	98	102	259	95	110	112	129	105	116	258	25	306	116	705
Gross Profit	350	363	351	366	381	411	411	466	443	450	475	506	506	546	506	534	559	615	567	633	693	761	698	809	807	805	764	860	870	753	806	914	943	959	793	929	868	1,173	763	1,092	3,896
Research & Development	48	44	45	40	47	66	63	56	51	57	60	62	80	97	86	79	79	92	77	133	141	155	130	139	149	173	189	209	234	217	223	221	200	241	181	190	241	171	134	208	754
Selling, General & Administrative	124	126	144	132	125	143	207	159	156	162	168	176	179	214	208	191	207	247	261	429	364	398	309	366	358	383	298	341	308	396	352	339	326	369	514	358	531	406	353	389	1,679
Total Operating Expenses	214	197	215	201	294	270	323	313	254	265	341	302	373	485	696	336	363	442	405	702	665	711	611	723	782	693	638	702	698	551	740	714	683	769	849	1,616	811	264	549	844	2,467
Operating Income	136	166	136	165	86	141	88	153	189	185	134	204	133	61	-190	198	196	173	162	-70	28	49	88	86	25	112	126	158	172	202	66	199	260	191	-56	-686	58	909	214	248	1,429
Interest Expense	18	19	19	18	19	21	21	20	19	18	18	18	18	18	18	26	27	28	27	69	93	89	71	63	80	74	74	73	71	90	66	62	59	51	54	47	49	45	63	37	194
Pre-Tax Income	116	151	116	141	65	119	65	129	169	165	114	183	113	39	-209	170	168	144	140	-135	-71	-48	2.2	19	-63	-340	54	80	100	62	-2.9	138	201	133	-110	-736	9.0	208	299	211	728
Income Tax Expense	29	34	29	36	1.2	-114	19	37	19	5.1	29	-79	11	-35	-51	55	19	11	18	229	-18	-12	0.5	-16	-43	-100	-15	-24	-47	-33	12	-31	-15	-58	-18	-17	-242	4.9	6.1	18	-213
Net Income	87	117	87	106	64	232	46	92	149	159	85	262	102	74	-158	115	148	133	122	-363	-53	-35	1.6	35	-20	-240	69	104	147	94	-15	169	215	191	-93	-718	251	203	293	193	941
EBITDA	191	207	165	196	212	206	145	255	240	294	250	271	252	239	216	269	278	281	235	82	190	517	341	317	297	249	345	313	334	361	269	363	424	397	139	-514	236	279	544	418	1,476

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings